2026 |
|
| 964. | Jain, Monika; Agrawal, Sashank; Cannac, Fabien; González-Páez, Gonzalo E; Lee, Wen-Hsin; Moskovitz, Re'em; Ketchem, Randal R; Williams, Katherine L; Emerling, Daniel E; Ward, Andrew B; Wilson, Ian A: Engineered antibodies preserve structural and functional recognition of Plasmodium falciparum circumsporozoite protein. In: Protein Sci, vol. 35, no. 9, pp. e70738, 2026, ISSN: 1469-896X. (Type: Journal Article | Abstract | Links)
@article{pmid42560026,
Long-lasting and highly effective malaria vaccines or monoclonal antibodies (mAbs) remain urgently needed, as current interventions show age-dependent benefits rather than broad protection across all ages. Recently, two highly protective human mAbs 224 (IGHV3-49/IGLV1-40) and 7088 (IGHV3-33/IGKV1-5), encoded by distinct germline genes, were re-engineered and renamed MAM01 and MS-1805, respectively, to extend serum half-life and enable low-cost, large-scale manufacturing in alignment with WHO guidelines. MAM01 completed Phase I and IIb clinical trials (safety/PK/challenge) in US healthy naive adults and is now in Phase I trials (age-de-escalation studies) in Uganda. Here, we determined crystal structures of the antigen-binding fragments (Fabs) of engineered MAM01, MS-1805, and 7088 in complex with different regions of the Plasmodium falciparum circumsporozoite protein (PfCSP), including junctional, minor, and major repeat regions. Notably, Fab 7088 features an extended CDRL3 comprising 10 amino acids (CDRL3:10) instead of the canonical 8 amino acid CDRL3 (CDRL3:8) typically observed in V3-33/V1-5-encoded mAbs, indicating unique folding within its germline context. In addition, cryo-EM structures of Fabs 7088 and MS-1805, in complex with recombinant shortened CSP (rsCSP), revealed a regular spiral configuration stabilized by homotypic Fab-Fab interactions, whereas 224 and MAM01 did not form such assemblies. Structural comparisons demonstrated that engineered antibodies retained key molecular and hydrogen-bond interactions without significant conformational changes, thereby maintaining antigen recognition and preserving binding affinity. These findings demonstrate that targeted framework engineering can enhance therapeutic potential while preserving structural integrity and function, providing insights for next-generation antibody-based interventions against malaria.
|
| 963. | Klasse, P J; Sanders, Rogier W; Ward, Andrew B; Wilson, Ian A; Moore, John P: Publisher Correction: The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies. 2026, ISSN: 1740-1534. (Type: Miscellaneous | Links)
@misc{pmid42722875,
|
| 962. | Walker, Simon M; Loutan, Arlo J; Tchesnokov, Egor P; Kocincova, Dana; Gordon, Calvin J; Escobedo, Ruby A; Jackson, Nathaniel; Vogel, Olivia A; Morsheimer, Kim; Park, Suncheol; Gharpure, Anant; Urbano, Ixchel; Heacock, Mina; Chen, Zhong; Pathak, Khushboo; Wolff, Karen C; Huerta, Lauren; Bakowski, Malina A; Riva, Laura; Gupta, Anil K; Yu, Chenguang; Das, Kalyan; Martinez-Sobrido, Luis; Basler, Christopher F; Davey, Robert; Wilson, Ian A; Ward, Andrew B; Chanda, Sumit; Chatterjee, Arnab K; Götte, Matthias: Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerases. In: J Biol Chem, vol. 302, no. 8, pp. 113316, 2026, ISSN: 1083-351X. (Type: Journal Article | Abstract | Links)
@article{pmid42409264,
Developing safe and effective treatments against emerging RNA viruses is an important goal in pandemic preparedness efforts. 4'-fluorouridine (4'-FlU) is a broad-spectrum antiviral that was shown to inhibit viral RNA-dependent RNA polymerases (RdRps). Given its notable range of antiviral activity, this class of nucleoside analogs warrants further investigation. Here, we studied the antiviral activity and underlying mechanism of inhibition of 4'-fluoroadenosine (4'-FlA). Like 4'-FlU, 4'-FlA demonstrates a broad-spectrum of antiviral activity against eight prototypic viruses representing diverse families. Enzyme kinetics shows that the triphosphate (4'-fluoroadenosine triphosphate) is efficiently incorporated by viral RdRps. A cryo-EM structure of the RdRp of severe acute respiratory syndrome coronavirus 2 in complex with double-stranded RNA and the incorporated monophosphate (4'-fluoroadenosine monophosphate) characterizes interactions at the active site. The incorporated analog elicits heterogeneous inhibition patterns in primer extension reactions. In contrast, templates with embedded 4'-fluoroadenosine monophosphate inhibit incorporation of complementary uridine triphosphate (UTP) across the viral RdRps. However, incorporation of 4'-fluoroadenosine triphosphate is not limited to viral polymerases and likewise includes human mitochondrial RNA polymerase. These results demonstrate the general potential for 4'-fluorinated nucleotides as antiviral drugs and guide the development of more selective derivatives for medical use in appropriate settings.
|
| 961. | Zhou, Panpan; Yuan, Meng; Zhang, Yuexiu; Limbo, Oliver; Song, Ge; Zhao, Fangzhu; Liu, Hejun; He, Wan-Ting; Capozzola, Tazio; Callaghan, Sean; Avillion, Gabriel; Li, Xuduo; Beutler, Nathan; Yong, Peter; Anzanello, Fabio; Rogers, Thomas F; Burton, Dennis R; Jardine, Joseph G; Wilson, Ian A; Andrabi, Raiees: Directed evolution of a stem-helix-targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity. In: PLoS Pathog, vol. 22, no. 8, pp. e1014393, 2026, ISSN: 1553-7374. (Type: Journal Article | Abstract | Links)
@article{pmid42566492,
Broadly neutralizing antibodies (bnAbs) targeting conserved regions of the betacoronavirus spike are important for pan-betacoronavirus protection and pandemic preparedness. Here, we report the isolation of a human monoclonal antibody, CC65.1, from a SARS-CoV-2 convalescent donor that targets the conserved S2 stem helix region. CC65.1 neutralizes various sarbecoviruses, including SARS-CoV-2, and binds to the MERS-CoV spike but lacks MERS-CoV-neutralizing activity due to insufficient binding affinity. We utilized directed evolution to enhance the binding affinity of CC65.1 for the MERS-CoV S2 stem helix, yielding engineered antibody variants with newly acquired MERS-CoV-neutralizing activity. High-resolution structural analysis reveals key paratope mutations that enhance binding and stabilize epitope engagement. Our findings demonstrate the potential of in vitro affinity maturation to expand the neutralization breadth of stem-helix-targeting antibodies across divergent betacoronaviruses. This work supports the development of engineered bnAbs for broadly protective betacoronavirus countermeasures and provides a strategy for achieving cross-lineage neutralization.
|
| 960. | Chen, Fang; Nguyen, Yen Thi Kim; Lee, Yi-Zong; Giang, Erick; Lau, Sing Chau; Koide, Yukiye; Hung, Shr-Hau; Ueno, Lynn A; He, Linling; Toth, Eric A; Fuerst, Thomas R; Lauer, Georg M; Stanfield, Robyn L; Zhu, Jiang; Wilson, Ian A; Law, Mansun: The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages. In: Cell Rep, vol. 45, no. 8, pp. 117760, 2026, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid42550688,
The bridging domain (BD) region on hepatitis C virus (HCV) E1E2 glycoprotein complex is a conserved, E1-dependent conformational site of vulnerability formed by E2 residues 646-704. Given its importance for rational vaccine design, here, we characterized the genetic, structural, functional, and epitope features of 25 BD-directed nAbs isolated from HCV-infected individuals or immunized macaques. These antibodies derive from diverse B cell lineages but frequently display recurrent CDRH3 motifs and recognize overlapping epitopes spanning antigenic regions AR4 and AR5, with variable engagement of the E2 back layer (BL) region. A crystal structure of the macaque nAb RM3-26 bound to E2 core domain reveals a BL-directed binding mode analogous to the human nAb hcab40. Importantly, BD-directed nAbs achieve broad neutralization with minimal somatic hypermutation at contact residues and act additively with neutralizing face-directed antibodies. Together, these findings underscore BD as a promising target for rational HCV vaccine design.
|
| 959. | Zhang, Yi-Nan; Zhu, Xueyong; Gomes, Keegan Braz; Lee, Yi-Zong; DesRoberts, Connor; He, Linling; Wilson, Ian A; Zhu, Jiang: Single-component self-assembling protein nanoparticles displaying stabilized prefusion-closed hemagglutinin trimers for influenza vaccine development. In: Nat Commun, vol. 17, no. 1, 2026, ISSN: 2041-1723. (Type: Journal Article | Abstract | Links)
@article{pmid42722670,
Current influenza vaccines primarily target hemagglutinin (HA), the major viral surface glycoprotein and principal determinant of neutralizing antibody (NAb) responses. However, antigenic drift and shift, together with HA's intrinsic metastability and low-pH sensitivity, limit broad and durable vaccine protection. Here, we stabilize HA in its prefusion-closed conformation through structure-guided amino acid substitutions. Targeting a conserved residue in the HA2 central triple helix-N95 in influenza A and Q95 in influenza B-provides a core design principle for modulating HA metastability across influenza A subtypes and both influenza B lineages, although the effects vary across viral groups. Using H1 CA09 and H3 HK68 as representative strains, we display stabilized HA trimers on 24-mer ferritin and 60-mer multilayered single-component self-assembling protein nanoparticles (SApNPs). In mice, HA-presenting SApNPs exhibit prolonged retention in lymph node follicles and elicit more robust germinal center responses compared with soluble trimers. Stabilized HA trimers and SApNPs induce functional antibody responses and confer varying levels of protection against homologous, heterologous, and cross-lineage viral challenges. Glycan modification enhances NAb induction or protection in some settings. Together, these findings provide mechanistic insights into HA metastability and establish a rational design framework for next-generation HA-based influenza vaccines.
|
| 958. | Naghizadeh, Mohammad; Flores-Garcia, Yevel; Moskovitz, Reem; Erdogan, Sayit Mahmut; Martin, Gregory M; Ofori, Ebenezer Addo; Plieskatt, Jordan; Cannac, Fabien; MacGill, Randall S; Nielsen, Morten Agertoug; Locke, Emily; King, C Richter; Miura, Kazutoyo; Birkett, Ashley; Soisson, Lorraine A; Sander, Adam F; Skogstrand, Kristin; Barfod, Lea; Salgado-Jimenez, Berenice; Borbye-Lorenzen, Nis; Wilson, Ian A; Ward, Andrew B; Zavala, Fidel; Theisen, Michael: Epitope-selective vaccine designs to elicit protective antibodies against the Plasmodium falciparum circumsporozoite protein. In: NPJ Vaccines, 2026, ISSN: 2059-0105. (Type: Journal Article | Abstract | Links)
@article{pmid42399255,
P. falciparum (Pf) malaria is a major cause of morbidity and mortality in sub-Saharan Africa. Recently introduced malaria vaccines, RTS,S/AS01 and R21/Matrix-M, are effective in preventing infection, but their efficacy declines over time. To address this challenge, next-generation vaccine candidates have been designed to improve the functional immunogenicity to the circumsporozoite protein (PfCSP). In this study, we tested multiple hypotheses for improved vaccine design. Immunogens were constructed to target regions containing functional epitopes, and these were displayed on a well-characterized clinically relevant particle display platform. These candidate vaccines were tested in the established infection mouse model in which P. berghei sporozoites have been engineered to contain PfCSP instead of the native PbCSP protein. Our results show that induction of antibodies to the junctional region and the minor and major repeats are all effective at reducing parasite infection of the liver, while antibodies to the C-terminal domain did not contribute to protective immunity. None of the domains showed evidence of antigenic competition when co-administered on separate particles or when expressed on the surface of a single particle. Immunogens expected to allow bivalent antibody binding were potently immunogenic while those with shorter structures permitting only 1-2 Fab binding interactions exhibited poor immunogenicity. No construct was found to be superior to the clinical benchmark RTS,S/AS01 in the mouse model. These results can inform approaches to malaria vaccine design and direct future research.
|
| 957. | Lv, Huibin; Feng, Ziqi; Teo, Qi Wen; Chen, Chunke; Gopal, Akshita B; Choi, Danbi; Tan, Timothy J C; Tang, Yun Sang; Siu, Lewis; Nourmohammad, Armita; Bruzzone, Roberto; Wilson, Ian A; Yuan, Meng; Wu, Nicholas C; Mok, Chris K P: Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants. In: Adv Sci (Weinh), pp. e76522, 2026, ISSN: 2198-3844. (Type: Journal Article | Abstract | Links)
@article{pmid42439327,
Rapid antigenic drift of the SARS-CoV-2 receptor-binding domain (RBD) underlies immune escape and continues to challenge the durability of antibody-mediated protection. Among the major classes of RBD-directed antibodies, germline-encoded IGHV3-53 responses are highly potent against early SARS-CoV-2 variants but are generally compromised by Omicron-associated mutations. Here, we identify an intrinsically cross-reactive IGHV3-53 germline antibody that recognizes multiple pre-Omicron variants, including SARS-CoV-2 wild-type, Alpha, and Delta. Notably, we demonstrate that targeted somatic evolution can further expand this breadth to overcome the immune escape of different Omicron variants. Guided by integrated structural and sequence analyses, we introduce four somatic mutations (G26E, T28I, S53P, and Y58F) into the germline antibody, resulting in markedly enhanced binding and neutralization of Omicron BA.1, and BA.4/5. High-resolution crystal structures reveal that these mutations re-establish interactions disrupted by substitutions in the Omicron RBD and improve binding at a remodeled epitope interface. Collectively, our findings define the structural basis by which specific mutations enhance cross-variant recognition of SARS-CoV-2. This work highlights the underappreciated breadth encoded within the naïve B-cell repertoire and provides a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
|
| 956. | Cho, So Yeon; Rantalainen, Kimmo; Ozorowski, Gabriel; Lu, Danny; Tingle, Ryan; Lee, Wen-Hsin; Ward, Andrew B; Schief, William R; Wilson, Ian A: Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies. In: Proc Natl Acad Sci U S A, vol. 123, no. 29, pp. e2609827123, 2026, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid42446980,
The membrane-proximal external region (MPER) of HIV-1 Env represents a critical target for broadly neutralizing antibodies (bnAbs) due to its conservation and functional importance. However, MPER-targeting bnAbs recognize composite epitopes comprising peptide and viral membrane lipid components, creating an inherent tension between viral neutralization efficacy and polyreactivity. 10E8-class antibodies exhibit high neutralization potency with low polyreactivity, whereas 4E10-class antibodies show comparably broad neutralization but higher polyreactivity, underscoring the need to understand the structural basis of this distinction. We therefore determined crystal structures of DH511.1 (memory B cell-derived), DH511.12P (plasma cell-derived), and VRC42.01 in complex with MPER peptide and phosphatidic acid, along with a cryo-EM reconstruction of DH511.2 bound to membrane-embedded Env. Through integrative analysis taking into account previously determined structures of other MPER bnAbs, we reveal two distinct lipid recognition strategies. Groove-mediated binders, including 10E8 and DH511, engage lipids through antibody-membrane interface grooves with distinct geometries and angular approaches to the membrane. In contrast, heavy chain-mediated binders, including 4E10, PGZL1, and VRC42, utilize positively charged CDR H1 patches for direct lipid headgroup recognition. Importantly, DH511 lineage members exhibited differential cardiolipin polyreactivity linked to their maturation stage. PGZL1 and VRC42.01 employ weaker positive patches at lipid-binding sites than 4E10, and PGZL1 additionally introduces a CDR H3-mediated negative patch that creates electrostatic repulsion with negatively charged lipid headgroups, thereby limiting nonspecific interactions. These findings provide a structural framework for understanding how MPER bnAbs balance lipid binding with specificity and inform immunogen design for inducing safe and effective neutralizing responses.
|
| 955. | Guenaga, Javier; Ádori, Monika; Bale, Shridhar; Phulera, Swastik; Zygouras, Ioannis; Schleich, Fabian-Alexander; Dopico, Xaquin Castro; Agrawal, Sashank; Ota, Miyo; Wilson, Richard; Cluff, Jocelyn; Dzvelaia, Tamar; Mandolesi, Marco; Lee, Wen-Hsin; Walsh, Agnes A; Melo, Mariane B; Verkoczy, Laurent; Irvine, Darrell J; Corcoran, Martin; Wilson, Ian A; Carnathan, Diane; Silvestri, Guido; Ward, Andrew B; Ozorowski, Gabriel; Hedestam, Gunilla B Karlsson; Wyatt, Richard T: Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex. In: Nature, vol. 654, no. 8119, pp. 777–785, 2026, ISSN: 1476-4687. (Type: Journal Article | Abstract | Links)
@article{pmid42056526,
As a chronically replicating virus, HIV has evolved extreme sequence variability and effective shielding of functionally constrained spike protein determinants by host-derived glycans. Broadly neutralizing antibodies, although rare, can be isolated from people living with HIV, revealing conserved envelope glycoprotein (Env) sites as key targets for vaccine development. One such target is the apex of the Env spike. Here we identify a vaccination strategy using heterologous HIV Env trimers covalently coupled to liposomes for multivalent display that resulted in the elicitation of cross-neutralizing HIV serum antibody responses in all trimer-liposome-immunized non-human primates. Critically, we isolated monoclonal antibodies from multiple macaques that cross-neutralize divergent HIV clinical isolates. High-resolution cryogenic electron microscopy structural analyses of monoclonal antibodies from four different macaques demonstrate that they target the Env trimer apex in a manner highly similar to that of the human-infection-elicited, apex-directed broadly neutralizing antibody PG9, representing a substantial advance in HIV vaccine development.
|
| 954. | Jain, Monika; Cannac, Fabien; Agrawal, Sashank; Lee, Wen-Hsin; Loeffler, Johannes R; Fernández-Quintero, Monica L; González-Páez, Gonzalo E; Moskovitz, Re'em; Ward, Andrew B; Wilson, Ian A: Structural basis for conserved and distinct antigen recognition by a lineage of malaria-protective antibodies. In: PLoS Pathog, vol. 22, no. 6, pp. e1014243, 2026, ISSN: 1553-7374. (Type: Journal Article | Abstract | Links)
@article{pmid42234703,
Monoclonal antibodies (mAbs) targeting the Plasmodium falciparum circumsporozoite protein (PfCSP) have demonstrated substantial promise in preventing malaria infection and disease. PfCSP is characterized by a central region composed of repetitive NANP motifs, which serve as major targets for protective antibodies. Several potent mAbs targeting this region exhibit homotypic Fab-Fab interactions, which enhance antigen binding and contribute to their neutralization potency. Among these, mAb 399, encoded by the IGHV3-49/IGKV2D-29 (VH3-49/VK2D-29) germline lineages, forms head-to-head inter-Fab contacts mediated primarily by germline-encoded residues. Here, we determined X-ray and cryo-EM structures of two additional Fabs, derived from the same germline lineages, 7160 and 7118, in their unliganded forms and with PfCSP-derived peptides or recombinant shortened CSP. Both Fabs bound NANP6 repeats with high affinity (KD 6-10 nM). Fab 7160 formed germline-encoded inter-Fab homotypic interactions resembling Fab 399, indicating a conserved and preconfigured mode of antigen recognition. In contrast, Fab 7118 does not form homotypic contacts and adopts a distinct binding mode, which precludes inter-Fab interactions. These findings highlight the structural versatility of VH3-49/VK2D-29-derived antibodies and demonstrate that their CDR loop variations can modulate antibody conformation, homotypic Fab-Fab interactions, and epitope engagement. Our study further defines this class of germline-encoded anti-CSP antibodies and provides mechanistic insights into how they achieve high-avidity binding and protective immunity either through or independent of pre-configured Fab-Fab interactions with important implications for germline-targeting malaria vaccine design.
|
| 953. | Dueker, Katharina; Capozzola, Tazio; Feng, Ziqi; Lin, Ryan N; Hurtado, Jonathan; Bangaru, Sandhya; Yuan, Meng; Beutler, Nathan; Garcia, Elijah; He, Wan-Ting; Callaghan, Sean; Avillion, Gabriel; Vo, Lina; Li, Xuduo; Torres, Jonathan L; Musharrafieh, Rami; Song, Ge; Mishra, Nitesh; Sharma, Pragati; Yong, Peter; Anzanello, Fabio; Michaels, Katarzyna Kaczmarek; Ben-Akiva, Elana; Silva, Murillo; Melo, Mariane; Makhdoomi, Muzamil; Westfall-Gomez, Ethan; Rinaldi, William; Ferguson, Melissa; Safonova, Yana; Crotty, Shane; Irvine, Darrell J; Rogers, Thomas; Ward, Andrew B; Briney, Bryan; Wilson, Ian A; Burton, Dennis R; Andrabi, Raiees: Heterologous betacoronavirus spike immunization in non-human primates elicits antibodies that neutralize both sarbeco- and merbecoviruses. In: Cell Rep, vol. 45, no. 6, pp. 117439, 2026, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid42241278,
In anticipation of future coronavirus (CoV) pandemics, developing vaccines that elicit broadly neutralizing antibodies (bnAbs) against diverse CoVs is critical. Here, we vaccinated rhesus macaques with the SARS-CoV-2 spike (S)-protein, then boosted with heterologous β-CoV S-proteins to focus responses to common conserved S2 bnAb epitopes. Initial SARS-CoV-2 priming elicited receptor-binding domain (RBD)-focused responses, while MERS-CoV boosting redirected responses toward the S2 region, including the stem-helix bnAb site. Although S2-directed serum cross-neutralization was undetectable and most isolated cross-reactive monoclonal antibodies (mAbs) targeted non-neutralizing epitopes, two S2 stem-helix mAbs were identified from memory B cells. These bnAbs neutralized diverse sarbeco- and merbecoviruses, including MERS-CoV, and conferred robust in vivo protection against SARS-CoV-2 challenge. Structural studies reveal that these macaque bnAbs closely mimic human S2 stem bnAbs induced by infection. These findings provide proof-of-principle for vaccination strategies that elicit broadly protective β-coronavirus responses and highlight non-human primates as a translational model for evaluating S2-targeted immunogens.
|
| 952. | Skelly, Ashwin N; Fan, Chengcheng; Keeffe, Jennifer R; Ökten, Arya B; Gavor, Edem; Newby, Maddy L; Allen, Joel D; Kreider, Edward F; Ding, Wenge; Osbaldeston, Rebecca A; Park, Younghoon; Connell, Andrew J; Lituchy, Melinda G; Bibollet-Ruche, Frederic; Radford, Katelyn M; West, Anthony P; Peña-Hernández, Mario A; Cruickshank, Kendra; Liu, Weimin; Li, Yingying; Albertus, Amie; McWilliams, Brieyanna; Russell, Ronnie M; Konrath, Kylie M; Torres, Jonathan L; Yuan, Meng; Gao, Hongmei; Montefiori, David C; Saag, Michael S; Goepfert, Paul A; Kulp, Daniel W; Ward, Andrew B; Wilson, Ian A; Shaw, George M; Andrabi, Raiees; Crispin, Max; Weissman, Drew; Wilen, Craig B; Bjorkman, Pamela J; Hahn, Beatrice H: mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model. In: Proc Natl Acad Sci U S A, vol. 123, no. 24, pp. e2536870123, 2026, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid42258728,
The unyielding antigenic drift of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the threat of future zoonotic sarbecovirus spillovers, has prompted the search for broadly neutralizing antibodies (bNAbs) to inform rational therapeutic and vaccine design. Here, we isolated and characterized 20 receptor binding domain (RBD)-directed bNAb lineages from a serially sampled SARS-CoV-2 patient who was infected and vaccinated during the early months of the pandemic. Thirteen of these targeted the highly conserved, cryptic class 1/4 or class 4 RBD epitopes and had long (18 to 26 amino acid) heavy chain complementarity determining region 3 loops that utilized the IGHD3-22 gene segment. Five bNAbs potently neutralized all 18 viruses in a panel containing SARS-CoV-2 variants up to the recently emerged XBB.1.5 and JN.1 strains as well as diverse sarbecoviruses from other clades. Structural analyses of the Ab401 and Ab568 bNAbs complexed with RBD and Spike trimer, respectively, revealed recognition features in common with other class 1/4 bNAbs. Prophylactic administration of Ab401 as a recombinant protein afforded robust protection against infectious challenge with either SARS-CoV-2_WA1 or a related bat sarbecovirus with zoonotic potential. A similar level of protection was achieved when the heavy and light chains of Ab401 were delivered as lipid nanoparticle-encapsulated mRNAs. These data expand the arsenal of SARS-CoV-2 bNAbs for clinical development and identify mRNA-based antibody delivery as a promising platform for both pandemic preparedness and protection of immunocompromised patients against emerging sarbecovirus variants.
|
| 951. | Fam, Kyong T; Chodisetti, Pavan Kumar; Wang, Zifei; Homer, Joshua A; Smedley, Christopher J; Kitamura, Seiya; Silva, Benjamin; Xiong, Yijun; Hansel-Harris, Althea; Holcomb, Matthew; Babarinde, Simeon; Turner, Adrianna M; Tyne, Daria Van; Wilson, Ian A; Forli, Stefano; Cravatt, Benjamin F; Park, Donghyun; Wolan, Dennis W; Moses, John E; Hang, Howard C: Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium. In: Nat Commun, vol. 17, no. 1, 2026, ISSN: 2041-1723. (Type: Journal Article | Abstract | Links)
@article{pmid42297812,
Vancomycin-resistant Enterococcus faecium (VREfm) is a leading cause of healthcare-associated infections globally and demands new approaches for treatment. Here we show that genetic and pharmacological inactivation of a highly conserved NlpC/P60 peptidoglycan hydrolase, secreted antigen A (SagA), enhanced vancomycin susceptibility of VREfm ex vivo and in vivo. Notably, genetic deletion of sagA impaired VREfm peptidoglycan remodeling, growth and increased the activity of vancomycin. We then identified first-in-class covalent NlpC/P60 peptidoglycan hydrolase inhibitors and demonstrated that pharmacological inactivation of SagA activity also impaired peptidoglycan remodeling and increased the efficacy of vancomycin across genetically distinct VREfm clinical isolates. Our study reveals peptidoglycan hydrolases are druggable targets whose inactivation improves the efficacy of vancomycin against VREfm.
|
| 950. | Li, Shuk Hang; Wang, Bo; Jo, Gyunghee; Mikelov, Artem; Atkinson, Reilly K; Sage, Valerie Le; Furey, Colleen; Ort, Jordan T; Ye, Naiqing; Gang, Sydney; Shah, Ruhi; Santos, Jefferson J S; Röltgen, Katharina; Joshi, Shilpa A; Lee, Ji-Yeun; Pursell, Taylor A; Drapeau, Elizabeth M; Han, Julianna; Callear, Amy P; Collman, Ronald G; Monto, Arnold S; Martin, Emily T; Lakdawala, Seema S; Ward, Andrew B; Wilson, Ian A; Boyd, Scott D; Hensley, Scott E: Childhood immunological imprinting of cross-subtype antibodies targeting the hemagglutinin head domain of influenza viruses. In: Cell Host Microbe, vol. 34, no. 5, pp. 873–887.e11, 2026, ISSN: 1934-6069. (Type: Journal Article | Abstract | Links)
@article{pmid42049037,
Influenza virus cross-subtype antibodies targeting epitopes in the hemagglutinin (HA) head are rare because these epitopes are variable between influenza virus subtypes. We found that a large proportion of monoclonal antibodies (mAbs) isolated from individuals immunized with the 2021-22 seasonal influenza vaccine bound to an epitope on the HA head of both the H1N1 vaccine strain and H3N2 strains from the mid-1990s. The unmutated common ancestors of many of these mAbs reacted to both the 1990s H3s and the 2021-22 H1 vaccine strain. These cross-subtype antibodies were also found in polyclonal sera, but only among individuals born in the 1990s. Ferrets sequentially exposed to a 1990s H3N2 virus and contemporary influenza vaccine also produced H1/H3 cross-reactive antibodies. Recently, H1N1 viruses have acquired a substitution that abrogates the binding of these antibodies. Together, our study demonstrates how prior influenza virus exposures can influence the specificity of antibodies elicited by entirely different influenza virus subtypes.
|
| 949. | Wu, Nelson R; Castro, Karla M; Beutler, Nathan; Lee, Wen-Hsin; Raghavan, Sai S R; Martin, Gregory M; Jain, Monika; Agrawal, Sashank; Liguori, Alessia; Kalyuzhniy, Oleksandr; Skog, Patrick D; Terada, Sierra; Lai, Yen-Chung; Ndihokubwayo, Justin; Lu, Danny; Eskandarzadeh, Saman; Alavi, Nushin; Phelps, Nicole; Tingle, Ryan; Youhanna, John E; Amirzehni, Sonya; Rogers, Thomas F; Burton, Dennis R; Wilson, Ian A; Ward, Andrew B; Correia, Bruno E; Schief, William R: Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes. In: Proc Natl Acad Sci U S A, vol. 123, no. 15, pp. e2521914123, 2026, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid41945436,
Malaria is a leading cause of disease in developing countries. The licensed malaria vaccine RTS,S/AS01 confers partial protection in part due to the elicitation of circumsporozoite protein (CSP) antibodies, of which those to the CSP repeat and junctional regions offer the most potent protection. Anti-repeat region antibodies, including the protective antibody L9, frequently develop mutations that promote inter-Fab contacts when bound to CSP in "spiral" quaternary structures. As a first step toward the design of immunogens that elicit L9-like antibodies, we utilized generative deep learning models to design epitope scaffolds that incorporated up to three junctional repeat epitopes with structural conformations and relative spatial orientations matching those of the multivalent complex of CSP bound to three copies of L9. Affinity and structural studies demonstrated accurate scaffolding of two epitopes with the intended relative orientation, and displacement of the third epitope, while maintaining inter-Fab contacts between L9 antibodies. In a mouse model of malaria liver invasion, immunization with nanoparticles displaying these scaffold immunogens inhibited liver invasion as potently as matched nanoparticles displaying a short junctional peptide but less potently than the same nanoparticles displaying longer junctional peptides. This study demonstrates a substantial advance for design of multiepitope scaffolds with predetermined relative epitope spatial positioning. The study also represents an initial step toward development of multiepitope immunogens to elicit antibodies that utilize homotypic interactions to bind pathogens in multivalent clusters.
|
| 948. | Bader, Daniel L V; Flynn, Claudia T; Kalyuzhniy, Oleksandr; Ozorowski, Gabriel; Corcoran, Martin M; Burns, Alison; Altman, Pilar; Rouzeau, Romy; Sincomb, Troy; Liguori, Alessia; Fernández-Quintero, Monica L; Loeffler, Johannes R; Torres, Jonathan L; Turner, Hannah L; Georgeson, Erik; Zhou, Amelia; Voic, Hannah; Goo, Sue; Shahin, Lara; Burton, Iszac; Wu, Mengyu; Stanfield, Robyn L; Eskandarzadeh, Saman; Lu, Danny; Alavi, Nushin; Phelps, Nicole; Tingle, Ryan; McKenney, Katherine; Youhanna, John; Amirzehni, Sonya; Schiffner, Torben; Steichen, Jon M; Burton, Dennis R; Wilson, Ian A; Hedestam, Gunilla B Karlsson; Landais, Elise; Lee, Jeong Hyun; Sok, Devin; Cottrell, Christopher A; Ward, Andrew B; Schief, William R: Structural and immunogenetic signatures guide CD4-mimetic HIV vaccine development. In: Cell Rep, vol. 45, no. 4, pp. 117180, 2026, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid41996239,
HIV vaccine strategies include aims to elicit broadly neutralizing antibodies (bnAbs) targeting the CD4-binding site, that are derived from immunoglobulin heavy-chain variable genes 1-2 (V1-2) and 1-46 (V1-46). Here, we present an integrated analysis of V1-46 bnAbs, including in vitro functional studies, cryo-electron microscopy structures of two V1-46 bnAbs (1-23 and 9-71) complexed with envelope trimers, and comprehensive structural and immunogenetic analyses, to help guide vaccine design. We show that V1-46-derived bnAbs use diverse light-chain variable (V/V) genes and LCDR3 lengths commonly found in human antibody repertoires, which generate unique LCDR3 signatures that influence both the antibody paratope and approach angle. We identify three V1-46 bnAb classes, 1B2530 (V1-47), CH235 (V3-15), and 561 (V3-20), with the 561 class further subdivided into types I and II. Our findings indicate that V1-46 priming immunogens should be tailored to each bnAb class, with 561-class bnAbs presenting optimal targets for germline-targeting vaccine design.
|
| 947. | Nguyen, Yen T K; Chen, Fang; Giang, Erick; Saha, Swati; Ueno, Lynn A; Chen, Christopher; Watson, Corey T; Tzarum, Netanel; Wilson, Ian A; Law, Mansun; Stanfield, Robyn L: Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2. In: NPJ Vaccines, vol. 11, no. 1, 2026, ISSN: 2059-0105. (Type: Journal Article | Abstract | Links)
@article{pmid42009696,
Hepatitis C continues to be a significant public health problem despite advancements in antiviral therapeutics. To eliminate this disease, an effective vaccine against new infections and re-infections is needed. However, to date only one Hepatitis C virus (HCV) envelope protein (E1E2) immunogen, developed by Chiron Inc., has been tested in a Phase I clinical trial (ClinicalTrials.gov identifier NCT00500747). To establish a benchmark for elicitation of broadly neutralizing antibodies (bnAbs) by E1E2, we previously immunized non-human primates (NHPs) with this immunogen and isolated monoclonal nAbs that exhibit neutralization potency comparable to human nAbs. Here we show that NHP nAbs, encoded by germline genes IGHV1-138*01 and IGHV4-NL_5*01 (homologs of human IGHV1-69*10 and IGHV4-59*12, respectively), recognize a relatively conserved E2 region (neutralizing face) proximal to antigenic region 3 (AR3). These NHP AR3-targeting nAbs share highly similar binding modes to human AR3-targeting nAbs, suggesting a similarity in human and NHP immune responses to the same HCV immunogen.
|
| 946. | Wang, Shengyang; Lin, Ting-Hui; Antonopoulos, Aristotelis; Kikuchi, Chika; Chapla, Digantkumar G; Valverde, Pablo; Moremen, Kelley W; Haslam, Stuart M; Wilson, Ian A; Paulson, James C: Chemoenzymatic Synthesis of N-Linked Glycan Receptors of H1N1 Influenza Virus on Human Airway Epithelial Cells. In: J Am Chem Soc, vol. 148, no. 11, pp. 12126–12138, 2026, ISSN: 1520-5126. (Type: Journal Article | Abstract | Links)
@article{pmid41810832,
Attachment of human influenza virus to the surface of airway epithelial cells is mediated by the hemagglutinin (HA) that binds to Neu5Acα2-6Gal-terminated glycans termed human-type receptors. Numerous reports suggest that current H1N1 and H3N2 influenza viruses that annually infect humans have evolved to preferentially recognize only a subset of human-type receptors. Based on glycomics analysis of nasal and tracheal human epithelial cells, we have defined and chemoenzymatically synthesized a novel library of α2-6 sialylated N-linked glycans that represent the diversity of structures that are candidate receptors of human influenza viruses. Using this library, we investigated the specificity of the HAs of H1N1 viruses stemming from two pandemics in 1918 and 2009. We find that H1N1 viruses from both pandemics have maintained a remarkably similar receptor specificity, with a strong preference for α2-6 sialylated biantennary N-linked glycans extended with two or more Galβ1-4GlcNAc (LacNAc) repeats on at least one antenna.
|
| 945. | Fu, Yanbin; Feng, Ziqi; Erickson, Steven A; Halfmann, Peter J; Li, Lei; Chervin, Jordan C; Troxell, Chloe A; Sun, Jiayi; Yasuhara, Atsuhiro; Changrob, Siriruk; Huang, Min; Zheng, Nai-Ying; Yuan, Meng; Kawaoka, Yoshihiro; Wilson, Ian A; Wilson, Patrick C: In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity. In: Cell Rep, vol. 45, no. 4, pp. 117137, 2026, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid41865371,
The epitope that monoclonal CR3022 binds to represents a promising target for broad protection against a wide range of human and zoonotic coronaviruses. We develop a powerful model to evaluate antibody affinity maturation in vivo using immunoglobulin (Ig)-humanized mice that express the predicted germline heavy chain of antibody CR3022. Severe acute respiratory syndrome coronavirus (SARS-CoV)/SARS-CoV-2 sequential immunization leads to the convergent evolution of the germline CR3022 through somatic hypermutation (SHM), resembling the affinity-matured CR3022 from a human but now also adapting to key variants and divergent sarbecoviruses. While simple prime-boost strategies drive CR3022-epitope targeting, an intensive vaccination protocol elicits dominant responses to other epitopes. X-ray crystal structures reveal that SARS-CoV-2-neutralizing CR3022-like antibodies exhibit enhanced affinity by increasing polar and electrostatic interactions. Overall, these findings show that CR3022-like clones can be readily adapted through SHM to increase breadth and potency to sarbecoviruses by relatively minor shifts in affinity with appropriate vaccination strategies.
|
| 944. | Kadam, Rameshwar U; Juraszek, Jarek; Brandenburg, Boerries; Garg, Divita; Zhu, Xueyong; Jongeneelen, Mandy; Tang, Chan; Schepens, Wim B G; Buyck, Christophe; Stoops, Bart; Vermond, Jan; Vogels, Ronald; Friesen, Robert H E; van Dongen, Maria J P; Wilson, Ian A: Small molecule-constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins. In: Proc Natl Acad Sci U S A, vol. 123, no. 13, pp. e2537533123, 2026, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid41875158,
Influenza continues to be a major threat to global health and a substantial economic burden. Innovative strategies are needed to tackle the growing resistance to established influenza therapeutics and to develop new therapeutics with novel mechanisms of action. Previous peptide and small molecule designs have been successful only against influenza group 1 hemagglutinin (HA). Here, we report on a CLIPS (Chemical Linkage of Peptides onto Scaffolds)-based approach to design potent peptidic inhibitors of influenza A viruses that now extend to both group 1 and group 2 HAs. This approach merges features of antibodies and small molecules to design constrained bicyclic peptides that engage the highly conserved HA stem. The heavy-chain complementarity-determining region 3 (HCDR3) of human broadly neutralizing antibody FI6v3 was grafted onto functionalized small molecule scaffolds. The designed peptides exhibited in vitro heterosubtypic cross-reactivity in binding to group 1 (H1 and H5) and group 2 (H3 and H7) HAs and in neutralization of H1N1, H5N1, and H7N3 viruses. A crystal structure of the bicyclic peptide with HA from H1N1 A/Puerto Rico/8/1934 (H1/PR8) at 2.35 Å resolution revealed that the designed peptide faithfully mimics the binding mode and functionality of the parent antibody FI6v3 to the highly conserved stem epitope. These structural and functional data illustrate how both group 1 and group 2 influenza A viruses can now be targeted by constrained peptidic ligands that should aid in development of pan-influenza therapeutics.
|
| 943. | Fam, Kyong T; Chodisetti, Pavan Kumar; Wang, Zifei; Homer, Joshua A; Smedley, Christopher J; Kitamura, Seiya; Silva, Benjamin; Xiong, Yijun; Hansel-Harris, Althea; Holcomb, Matthew; Babarinde, Simeon; Turner, Adrianna M; Tyne, Daria Van; Wilson, Ian A; Forli, Stefano; Cravatt, Benjamin F; Park, Donghyun; Wolan, Dennis W; Moses, John E; Hang, Howard C: Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant . In: bioRxiv, 2026, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid41889990,
Vancomycin-resistant (VREfm) is a leading cause of healthcare-associated infections globally and demands new approaches for treatment. Here we show that genetic and pharmacological inactivation of a highly conserved NlpC/P60 peptidoglycan hydrolase, secreted antigen A (SagA), enhanced vancomycin susceptibility of VREfm and . Notably, genetic deletion of impaired VREfm peptidoglycan remodeling, growth and increased the activity of vancomycin. We then identified first-in-class covalent NlpC/P60 peptidoglycan hydrolase inhibitors and demonstrated that pharmacological inactivation of SagA activity also impaired peptidoglycan remodeling and increased the efficacy of vancomycin across genetically distinct VREfm clinical isolates. Our study reveals peptidoglycan hydrolases are druggable targets whose inactivation improves the efficacy of vancomycin against VREfm.
|
| 942. | Park, Suncheol; Mischka, Jacob; Okba, Nisreen; Abbad, Anass; Yuan, Meng; Srivastava, Komal; Gleason, Charles; Mulder, Lubbertus C F; Copps, Jeffrey; Saam, Katrina; Bangaru, Sandhya; Krammer, Florian; Wilson, Ian A; Simon, Viviana; Ward, Andrew B: The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response. In: bioRxiv, 2026, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid41756886,
The continued mutational pressure on the SARS-CoV-2 S1 subunit underscores the need to target the conserved S2 region for pan-coronavirus vaccine development. A detailed molecular understanding of S2-directed immune responses is therefore essential. In this study, we identified the S2 apex as the most immunodominant epitope within the S2 subunit, eliciting robust antibody responses despite occlusion by S1, using electron-microscopy-based polyclonal epitope mapping (EMPEM) of plasma from infected and vaccinated individuals. Structure-guided sequence analysis with antibody databases revealed that antibodies targeting a poorly characterized S2 Apex-B site form a convergent public clonotype, which is predominantly derived from the IGHV3-30 germline with a 14-residue CDRH3 containing a G/S-G-S/N-Y motif. This clonotype is extensively expanded, accounting for up to 40% of total spike-reactive antibody sequence counts in individual vaccinated donors. This study elucidates the molecular basis the high-frequency elicitation of this non-neutralizing clonotype emphasizing that its immunodominance acts as a primary hurdle for universal coronavirus vaccines and underscore the need for precision antigen design to redirect immunity toward more potent neutralizing targets.
|
| 941. | Weber, Julia; Ponse, Niels L D; Zhu, Xueyong; Carrasco, María Ríos; Han, Alvin X; Funk, Mathis; Lin, Ting-Hui; García, Alba Gabarroca; Spruit, Cindy M; Zhang, Ding; Yu, Wenli; Wilson, Ian A; Richard, Mathilde; Boons, Geert-Jan; de Vries, Robert P: The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans. In: PLoS Pathog, vol. 22, no. 1, pp. e1013812, 2026, ISSN: 1553-7374. (Type: Journal Article | Abstract | Links)
@article{pmid41557749,
Highly pathogenic H5Ny influenza A viruses are causing unprecedented, season-independent outbreaks across avian and mammalian species, including dairy cattle, a novel reservoir. The sialoside-binding properties of influenza A hemagglutinin (HA) are strongly related to its ability to infect and transmit between hosts. Mucin-like O-glycans, omnipresent in respiratory tracts, have been understudied as viral receptors due to their complexity. To address this, we synthesized 25 O-linked glycans with diverse sialosides, including modifications by fucosides and sulfates. Our findings reveal that H5Ny 2.3.4.4b viruses bind core 3 sialyl-Lewisx and Sia-Gal-β3GalNAc, O-linked glycans not recognized by classical H5 or other avian viruses. By determining crystal structures, we resolved the structural features of four glycans in an H5 hemagglutinin (HA) from a 2016 2.3.4.4b virus. While these viruses do not bind human-type receptors, their broad receptor specificity enhances binding to human tracheal tissues, suggesting that O-glycan recognition could contribute to the continues spillover of this clade.
|
| 940. | Dueker, Katharina; Capozzola, Tazio; Feng, Ziqi; Lin, Ryan N; Hurtado, Jonathan; Bangaru, Sandhya; Yuan, Meng; Beutler, Nathan; Garcia, Elijah; He, Wan-Ting; Callaghan, Sean; Avillion, Gabriel; Vo, Lina; Li, Xuduo; Torres, Jonathan L; Musharrafieh, Rami; Song, Ge; Mishra, Nitesh; Sharma, Pragati; Yong, Peter; Anzanello, Fabio; Kaczmarek-Michaels, Kasia; Ben-Akiva, Elana; Silva, Murillo; Melo, Mariane; Makhdoomi, Muzamil; Westfall-Gomez, Ethan; Rinaldi, William; Ferguson, Melissa; Safonova, Yana; Crotty, Shane; Irvine, Darrell J; Rogers, Thomas; Ward, Andrew B; Briney, Bryan; Wilson, Ian A; Burton, Dennis R; Andrabi, Raiees: Heterologous betacoronavirus spike immunization in nonhuman primates elicits cross-reactive antibodies that neutralize both sarbeco- and merbecoviruses. In: bioRxiv, 2026, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid41648252,
In anticipation of future coronavirus (CoV) pandemics, developing vaccines that elicit broadly neutralizing antibodies (bnAbs) against diverse CoVs is critical. Here, we vaccinated rhesus macaques with SARS-CoV-2 spike (S)-protein, then boosted with heterologous β-CoV S-proteins to focus responses to common conserved S2 bnAb epitopes. Initial SARS-CoV-2 priming elicited receptor-binding domain (RBD)-focused responses, while MERS-CoV boosting redirected responses toward the S2 region, including the stem-helix bnAb site. Although S2-directed serum cross-neutralization was undetectable and most isolated cross-reactive monoclonal antibodies (mAbs) targeted non-neutralizing epitopes, two S2 stem-helix mAbs were identified from memory B cells. These bnAbs neutralized diverse sarbeco- and merbecoviruses, including MERS-CoV, and conferred robust protection against SARS-CoV-2 challenge. Structural studies revealed that these macaque bnAbs closely mimic human S2-stem bnAbs induced by infection. These findings provide proof-of-principle for vaccination strategies that elicit broadly protective β-coronavirus responses and highlight non-human primates as a translational model for evaluating S2-targeted immunogens.
|
2025 |
|
| 939. | Changrob, Siriruk; Yasuhara, Atsuhiro; Park, Suncheol; Bangaru, Sandhya; Li, Lei; Troxell, Chloe A; Halfmann, Peter J; Erickson, Steven A; Catanzaro, Nicholas J; Yuan, Meng; Zhou, Panpan; Huang, Min; Wilbanks, G Dewey; McGrath, Joshua J C; Singh, Gagandeep; Nelson, Sean A; Fu, Yanbin; Zheng, Nai-Ying; Carayannopoulos, Sofia M; Dugan, Haley L; Shaw, Dustin G; Stamper, Christopher T; Madariaga, Maria Lucia L; Krammer, Florian; Andrabi, Raiees; Burton, Dennis R; Ward, Andrew B; Wilson, Ian A; Kawaoka, Yoshihiro; Wilson, Patrick C: Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. In: J Exp Med, vol. 222, no. 12, 2025, ISSN: 1540-9538. (Type: Journal Article | Abstract | Links)
@article{pmid41066082,
The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses.
|
| 938. | Lee, Yi-Zong; Zhang, Yi-Nan; Newby, Maddy L; Ward, Garrett; Gomes, Keegan Braz; Auclair, Sarah; DesRoberts, Connor; Allen, Joel D; Ward, Andrew B; Stanfield, Robyn L; He, Linling; Crispin, Max; Wilson, Ian A; Zhu, Jiang: Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification. In: Nat Commun, vol. 16, no. 1, pp. 11368, 2025, ISSN: 2041-1723. (Type: Journal Article | Abstract | Links)
@article{pmid41387700,
Filoviruses pose a significant threat to human health due to frequent outbreaks and high mortality. Although two vector-based vaccines are available for Ebola virus, a broadly protective filovirus vaccine remains elusive. Here, we evaluate a general strategy for stabilizing glycoproteins (GP) from Ebola, Sudan, and Bundibugyo orthoebolaviruses, as well as Ravn orthomarburgvirus. A 3.2 Å crystal structure provides atomic-level details of the redesigned Ebola virus GP, while cryo-electron microscopy reveals how a pan-orthoebolavirus neutralizing antibody targets a conserved site on the stabilized Sudan virus GP (3.13 Å resolution), along with a low-resolution model of antibody-bound Ravn virus GP. A self-assembling protein nanoparticle (SApNP), I3-01v9, is redesigned at the N terminus to enable optimal surface display of filovirus GP trimers. Following detailed in vitro characterization, we examine the lymph node dynamics of Sudan virus GP and GP-presenting SApNPs in mice. Compared with the soluble trimer, SApNPs exhibit ~112-fold longer retention in lymph node follicles, up to 28-fold greater presentation on follicular dendritic cell dendrites, and up to 3-fold stronger germinal center reactions. Functional antibody responses induced by filovirus GP trimers and SApNPs bearing wild-type or modified glycans are assessed in mice. This study provides a foundation for next-generation filovirus vaccine development.
|
| 937. | Agrawal, Sashank; Jain, Monika; Marinelli, Daniella; Cho, So Yeon; Briney, Bryan; Wilson, Ian A: Structural hijacking of FcRn by human astrovirus spikes reveals conserved epitopes for broad-spectrum antivirals. In: Cell Rep, vol. 44, no. 12, pp. 116679, 2025, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid41389202,
Human astroviruses (HAstVs) are a leading cause of pediatric gastroenteritis and emerging systemic infections; however, no targeted therapies exist. A critical barrier to intervention has been the lack of molecular insights into viral entry, particularly the interaction between the HAstV capsid spike and its receptor, the neonatal Fc receptor (FcRn). Here, we report crystal structures of the HAstV spike from classical serotypes 2 and 6 in complex with human FcRn at 3 Å resolution, defining a conserved receptor-binding interface at atomic resolution. These structures reveal serotype-specific variations that dictate receptor affinity and demonstrate that reported neutralizing antibodies can inhibit infection by sterically blocking the receptor-binding site. Mapping conserved epitopes across classical HAstV serotypes provides a blueprint for designing broad-spectrum antivirals that disrupt viral entry. Notably, our structural data rationalize the potential repurposing of clinical FcRn inhibitors, such as nipocalimab, to block HAstV infection, bridging critical gaps in astrovirus biology and antiviral development.
|
| 936. | Kadam, Rameshwar U; Juraszek, Jarek; Brandenburg, Boerries; Garg, Divita; Zhu, Xueyong; Jongeneelen, Mandy; Schepens, Wim B G; Stoops, Bart; Vermond, Jan; Goutier, Wouter; Tang, Chan; Blokland, Sven; Vogels, Ronald; Friesen, Robert H E; van Dongen, Maria J P; Wilson, Ian A: VH antibody loop guides design of a synthetic macrocyclic peptide that potently blocks influenza virus membrane fusion. In: Npj Viruses, vol. 3, no. 1, pp. 83, 2025, ISSN: 2948-1767. (Type: Journal Article | Abstract | Links)
@article{pmid41413306,
Miniaturizing biologically complex structural motifs to produce synthetic functional mimetics holds significant promise for development of new therapeutic modalities. Here, we demonstrate a unique approach using the key binding loop of the single variable domain of a heavy chain (VH) llama antibody as a starting point for peptide design. VH antibodies of camelids and sharks generally have longer, but more ligand-efficient complementarity determining region 3 (CDR3) loops and are relatively stable structures. We harnessed these attributes as templates for design of a series of synthetic macrocyclic peptides. The designed peptides exhibit nanomolar binding to influenza hemagglutinin (HA) and heterosubtypic in vitro neutralization breadth against influenza A viruses by inhibiting the low pH mediated HA conformational changes that lead to membrane fusion. X-ray structures of peptide-HA complexes reveal high structural mimicry with the parent VH antibody. One such macrocycle peptide candidate is promising for further development of broad protection against influenza A group 1 viruses.
|
| 935. | Klasse, P J; Sanders, Rogier W; Ward, Andrew B; Wilson, Ian A; Moore, John P: The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies. In: Nat Rev Microbiol, vol. 23, no. 11, pp. 734–752, 2025, ISSN: 1740-1534. (Type: Journal Article | Abstract | Links)
@article{pmid40702326,
To end the AIDS pandemic, an effective vaccine is sought to prevent new infections by inducing broadly active HIV-1 neutralizing antibodies. Monoclonal neutralizing antibodies can be administered therapeutically to people living with HIV-1 and preventively to those who are uninfected and at risk. Neutralizing antibodies block viral entry into susceptible cells by targeting the HIV-1 envelope glycoprotein, which mediates entry by membrane fusion. The envelope glycoprotein evades neutralizing antibody responses by multiple means, including extreme sequence variation and a dense protective glycan shield. Despite these impediments, many broadly active neutralizing human antibodies have been isolated, typically after years of HIV-1 infection. In this Review, we describe how such antibodies target distinct epitope clusters that cumulatively now cover most of the external surface of the envelope glycoprotein. These antibodies vary in potency, in the degree to which they reduce infectivity, in mechanism of action, and in structural basis, affinity and kinetics of binding. Broadly neutralizing antibody responses have, however, so far not been elicited by immunization with envelope glycoproteins. That situation may change though with the rapid advancement of structure-guided immunogen design strategies that engage germline versions of human antibodies and guide their maturation towards greater neutralization potency and breadth.
|
| 934. | Feng, Ziqi; Kose, Nurgun; Moreira, Fernando R; Kimpel, Anne L M; Copps, Jeffrey; Suryadevara, Naveenchandra; Jackson, Daniel J; Gern, James E; Wilson, Ian A; Li, Sheng; de Vries, Robert P; Baric, Ralph S; Bangaru, Sandhya; Crowe, James E; Ward, Andrew B: Human coronavirus HKU1 neutralization by glycan receptor mimicry. In: bioRxiv, 2025, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid41278654,
Entry of seasonal human coronavirus HKU1 (HCoV-HKU1) into host cells is facilitated by sequential binding to sialoglycans and transmembrane serine protease 2 (TMPRSS2) receptors. However, the neutralizing capacity of antibodies disrupting these receptor interactions have not been examined. Here, we describe the isolation and characterization of a human monoclonal antibody (mAb) HKU1-2 that recognizes the HCoV-HKU1 spike protein and exhibits dose-dependent neutralization of the virus. Epitope mapping and structural analysis revealed that HKU1-2 mAb targets the sialoglycan binding site in the N-terminal domain of the spike protein. A cryo-electron microscopy (cryo-EM) structure of the spike-Fab complex further demonstrated the ability of HKU1-2 to mimic sialic acid binding thereby effectively blocking sialoglycan receptor engagement. HKU1-2 binding is primarily mediated by CDRH3 recognition of NTD residues K80 and W89 that are known to be critical for sialic acid engagement. Overall, our results demonstrate antibody recognition and neutralization of HCoV-HKU1 by receptor mimicry.
|
| 933. | Martyn, Gregory D; Kalagiri, Rajasree; Veggiani, Gianluca; Stanfield, Robyn L; Choudhuri, Indrani; Sala, Margaux; Meisenhelder, Jill; Chen, Chao; Biswas, Avik; Levy, Ronald M; Lyumkis, Dmitry; Wilson, Ian A; Hunter, Tony; Sidhu, Sachdev S: Using phage display for rational engineering of a higher-affinity humanized 3' phosphohistidine-specific antibody. In: Commun Chem, vol. 8, no. 1, pp. 381, 2025, ISSN: 2399-3669. (Type: Journal Article | Abstract | Links)
@article{pmid41310398,
Histidine phosphorylation is a non-canonical post-translational modification (PTM), with 1-phosphohistidine (1-pHis) and 3-phosphohistidine (3-pHis) isoforms, that is understudied due to a lack of robust reagents, including high-affinity pHis-specific antibodies. Engineering pHis antibodies is challenging due to the labile nature of its phosphoramidate (P-N) bond. We developed a strategy for in vitro engineering of antibodies for the detection of native 3-pHis targets, in which the rabbit SC44-8 anti-3-pTza mAb is humanized into a scaffold (hSC44) that is suitable for phage display. Six unique Fab phage-displayed hSC44 scaffold libraries were screened for antibodies that bound 3-pHis with higher affinity and had specificity for 3-pHis versus 3-pTza. hSC44.20N32F, the best engineered antibody, has ~10-fold higher affinity for 3-pHis than parental hSC44. Eleven new Fab structures, including the first antibody-pHis peptide structures, together with structural and quantum mechanical calculations, provided molecular insights into 3-pHis and 3-pTza discrimination by hSC44.20N32F and the increased affinity obtained through engineering. We demonstrated the utility of these high-affinity 3-pHis-specific antibodies for the recognition of pHis proteins in mammalian cells by immunoblotting and immunofluorescence staining. Our work describes a general method for engineering labile PTM-specific antibodies and provides novel antibodies for investigating the role of 3-pHis in cell biology.
|
| 932. | Feng, Ziqi; Teo, Qi Wen; Ibrahim, Barikisu A; Liu, Wenkan; Zhang, Ding; Mao, Kevin J; Shao, Evan K; Gregory, Devon A; Wilson, Ian A; Johnson, Marc C; Yuan, Meng; Wu, Nicholas C: A highly divergent cryptic SARS-CoV-2 lineage exhibits strong receptor binding and immune evasion. In: medRxiv, 2025. (Type: Journal Article | Abstract | Links)
@article{pmid41332825,
SARS-CoV-2 genomic surveillance in wastewater enables the identification of cryptic lineages, often with numerous mutations not observed in circulating variants. Here, we discovered a unique cryptic SARS-CoV-2 lineage (designated NJ) from New Jersey wastewater that carries many rare mutations and exhibits the highest binding affinity to the hACE2 receptor among all tested SARS-CoV-2 variant RBDs, including the latest Omicron lineages. Moreover, NJ shows extensive evasion against all five major classes of neutralizing antibodies to SARS-CoV-2. Deep mutational scanning further demonstrates the involvement of epistasis in the evolution of the NJ-RBD. Crystal structures of NJ-RBD in complex with hACE2 and with a broadly neutralizing antibody CC25.4 reveal key amino acid substitutions that affect receptor binding, antibody evasion, and explain its unique molecular characteristics. Overall, these findings not only elucidate the structural and functional features of a cryptic SARS-CoV-2 lineage, but also provide insights into potential future evolution of SARS-CoV-2.
|
| 931. | Nair, Usha; Feng, Ziqi; Akauliya, Madhav; Esposito, Abigail G; Crain, Charles R; Lamperti, Edward D; Prum, Thavaleak; Warner, John E; Madungwe, Lisa; Dale, Gordon A; Boucau, Julie; Gaiha, Gaurav D; Yuan, Meng; Wilson, Ian A; Batista, Facundo D: In vivo antibody diversification targeting a conserved coronavirus epitope. In: J Exp Med, vol. 222, no. 10, 2025, ISSN: 1540-9538. (Type: Journal Article | Abstract | Links)
@article{pmid40674170,
To explore the use of human B cell receptor (BCR) knock-in mice for broadening antibody responses, we diversified CR3022, a monoclonal antibody (mAb) originally identified in a 2003 severe acute respiratory syndrome coronavirus (SARS-CoV) convalescent patient. This mAb targets a conserved epitope on the coronavirus receptor-binding domain (RBD). We took advantage of high- and low-affinity CR3022 BCR knock-in mice and immunized them with SARS-CoV-2 Wuhan RBD trimers to expand the breadth of these antibodies toward this virus. The resulting antibodies retained the ability to neutralize SARS-CoV and exhibited enhanced affinity and neutralization against the SARS-CoV-2 WA1/2020 strain, as well as the Delta (B.1.617.2) and Omicron KP.3 variants. They also showed broadened reactivity to two bat coronaviruses: WIV1 and, to a lesser potency, BtKY72. Structural analysis revealed key mutations that enhanced binding and neutralization, highlighting the importance of epitope accessibility and variant-specific conformations in antibody diversification. These findings demonstrate that human BCR-expressing mouse models can generate effective antibodies with broad neutralizing activity against viral epitopes.
|
| 930. | Fantin, Raianna F; Yuan, Meng; Park, Seok-Chan; Bozarth, Bailey; Cohn, Hallie; Ignacio, Maxinne; Earl, Patricia; Civljak, Alesandro; Laghlali, Gabriel; Zhang, Ding; Zhu, Xueyong; Crandell, Jameson; Monteiro, Valter; Clark, Jordan J; Cotter, Catherine; Burkhardt, Martin; Singh, Gagandeep; Warang, Prajakta; Diego, Juan García-Bernalt; Srivastava, Komal; Lugo, Luz A; Pischel, Lauren; ; Yildirim, Inci; Omer, Saad B; da Silva, Daniel; Krammer, Florian; Bajic, Goran; Simon, Viviana; Schotsaert, Michael; Lucas, Carolina; Wilson, Ian A; Moss, Bernard; Coelho, Camila H: Human monoclonal antibodies targeting A35 protect from death caused by mpox. In: Cell, vol. 188, no. 22, pp. 6236–6252.e18, 2025, ISSN: 1097-4172. (Type: Journal Article | Abstract | Links)
@article{pmid40865529,
The 2022 mpox outbreak highlighted the serious threat of monkeypox virus (MPXV), yet effective treatments are lacking. From an mpox-convalescent individual, we identified three high-affinity human monoclonal antibodies (mAbs) (named EV35-2, EV35-6, and EV35-7) that target the A35 protein in MPXV. These antibodies block viral spread in vitro and protect mice against lethal MPXV and vaccinia virus infection via both Fc-dependent and independent mechanisms. Levels of serum antibodies targeting the same epitopes are increased in mpox-convalescent humans, and higher levels of these antibodies in the sera are linked to shorter symptom duration and no hospitalization. Systems-level multivariate analysis indicated that mpox-convalescent serum antibodies targeting the same epitopic region as these three mAbs may function cooperatively, with additive associations to clinical protection. Two of the antibodies use a conserved IGHD2-21-encoded CxGGDCx motif in their CDRH3 region to bind a highly conserved poxvirus epitope. These findings establish A35 as a critical therapeutic target and highlight A35-specific mAbs as promising candidates for next-generation orthopoxvirus treatments.
|
| 929. | Zhu, Xueyong; Khalil, Ahmed M; Piepenbrink, Michael S; Yu, Wenli; Ma, Yao; Martinez-Sobrido, Luis; Wilson, Ian A; Kobie, James J: Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation. In: Commun Biol, vol. 8, no. 1, pp. 1427, 2025, ISSN: 2399-3642. (Type: Journal Article | Abstract | Links)
@article{pmid41053391,
Monoclonal antibodies (mAbs) that recognize and inhibit a diverse range of influenza viruses, although relatively rare, have been isolated following infection or vaccination. Study of their ontology and mechanisms of action informs universal vaccine and therapeutic development. We have previously described a potent and broad neuraminidase (NA)-neutralizing human mAb, 1122A11, that neutralizes a wide range of H3N2 viruses. Here, further characterization of 1122A11 reveals reactivity to cross-group influenza A virus NAs, including group-1 N1 and N8, and group-2 N2 and N3 NAs. Recent H3N2 viruses have acquired Asn245 glycosylation on the active site rim. Crystal structures of an N2 NA from A/Singapore/INFIMH-16-0019/2016 (H3N2) at 2.3 Å (apo) and 2.2 Å (Fab bound) resolution showed that 1122A11 binding causes local changes to the periphery of NA active site to accommodate the glycan. The CDRH3 of 1122A11 inserts into the active site and mimics the substrate sialic acid. We then determined that the ability of 1122A11 to protect from lethal challenge in mice is not dependent on Fc-effector function. These results highlight the therapeutic potential of 1122A11 as a broad protective anti-viral and reinforce pursuit of immunogen development of NA antibodies toward achieving more universal influenza protection.
|
| 928. | Zhou, Panpan; Yuan, Meng; Zhang, Yuexiu; Limbo, Oliver; Song, Ge; Zhao, Fangzhu; Liu, Hejun; He, Wan-Ting; Capozzola, Tazio; Callaghan, Sean; Avillion, Gabriel; Li, Xuduo; Beutler, Nathan; Yong, Peter; Anzanello, Fabio; Rogers, Thomas F; Burton, Dennis R; Jardine, Joseph G; Wilson, Ian A; Andrabi, Raiees: Directed evolution of a stem-helix-targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity. In: bioRxiv, 2025, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid41256381,
Broadly neutralizing antibodies (bnAbs) targeting conserved regions of the betacoronavirus spike are important for pan-betacoronavirus protection and pandemic preparedness. Here, we report on the isolation of a human monoclonal antibody, CC65.1, from a SARS-CoV-2 convalescent donor that targets the conserved S2 stem helix region. CC65.1 neutralizes various sarbecoviruses, including SARS-CoV-2, and binds the MERS-CoV spike but lacks MERS-CoV-neutralizing activity due to insufficient binding affinity. We utilized directed evolution to enhance the binding affinity of CC65.1 for the MERS-CoV S2 stem helix, yielding engineered antibody variants with newly acquired MERS-CoV-neutralizing activity. High-resolution structural analysis reveals key paratope mutations that optimize binding and stabilize epitope engagement. Our findings demonstrate the potential of rational antibody engineering to expand bnAb breadth across divergent betacoronaviruses. This work supports the development of engineered bnAbs and S2-targeted vaccines for broad betacoronavirus countermeasures and highlights strategies to achieve cross-lineage immunity for future pandemic threats.
|
| 927. | Lee, Yi-Zong; Zhang, Yi-Nan; Newby, Maddy L; Ward, Garrett; Gomes, Keegan Braz; Auclair, Sarah; DesRoberts, Connor; Allen, Joel D; Ward, Andrew B; Stanfield, Robyn L; He, Linling; Crispin, Max; Wilson, Ian A; Zhu, Jiang: Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification. In: bioRxiv, 2025, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid40060701,
Filoviruses pose a significant threat to human health due to frequent outbreaks and high mortality. Although two vector-based vaccines are available for Ebola virus, a broadly protective filovirus vaccine remains elusive. Here, we evaluate a general strategy for stabilizing glycoprotein (GP) structures from Ebola, Sudan, and Bundibugyo orthoebolaviruses and Ravn orthomarburgvirus. A 3.2 Å crystal structure provides atomic-level details of the redesigned Ebola virus GP, while cryo-electron microscopy reveals how a pan-orthoebolavirus neutralizing antibody targets a conserved site on the stabilized Sudan virus GP (3.13 Å resolution), along with a low-resolution model of antibody-bound Ravn virus GP. A self-assembling protein nanoparticle (SApNP), I3-01v9, is redesigned at the N terminus to enable optimal surface display of filovirus GP trimers. Following detailed in vitro characterization, we examine the lymph node dynamics of Sudan virus GP and GP-presenting SApNPs in mice. Compared with the soluble trimer, SApNPs exhibit ~112-fold longer retention in lymph node follicles, up to 28-fold greater presentation on follicular dendritic cell dendrites, and up to 3-fold stronger germinal center reactions. Functional antibody responses induced by filovirus GP trimers and SApNPs bearing wild-type and modified glycans are assessed in mice. This study provides a foundation for next-generation filovirus vaccine development.
|
| 926. | Lin, Xiaohe; Cottrell, Christopher A; Kalyuzhniy, Oleksandr; Tingle, Ryan; Kubitz, Michael; Lu, Danny; Yuan, Meng; Schief, William R; Wilson, Ian A: Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial. In: Proc Natl Acad Sci U S A, vol. 122, no. 33, pp. e2510163122, 2025, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid40789024,
The development of germline-targeting vaccines represents a potentially transformative strategy to elicit broadly neutralizing antibodies (bnAbs) against HIV and other antigenically diverse pathogens. Here, we report on structural characterization of vaccine-elicited VRC01-class bnAb precursors in the IAVI G001 Phase 1 clinical trial with the eOD-GT8 60mer nanoparticle as immunogen. High-resolution X-ray structures of eOD-GT8 monomer complexed with Fabs of five VRC01-class bnAb precursors with >90% germline identity revealed a conserved mode of binding to the HIV CD4-binding site via IGHV1-2-encoded heavy chains, mirroring mature bnAb interactions. The light-chain V-gene diversity emulated VRC01 bnAbs and stabilized antigen engagement, while their conserved five-residue LCDR3 motifs prevented steric clashes. Notably, the VRC01-class bnAb precursors accommodated the N276 glycan, a key barrier in HIV Env recognition, through structural rearrangements in HCDR3 or LCDR1, despite its absence in the immunogen. Surface plasmon resonance analysis showed that 87% of elicited antibodies retained glycan binding capacity, albeit with reduced affinity. These findings validate the ability of eOD-GT8 60mer nanoparticles to prime VRC01-class bnAb precursors with native-like paratopes but with intrinsic glycan adaptability. Structural mimicry of mature bnAbs was observed even with limited somatic hypermutation, indicating that critical features are encoded in the germline repertoire. The structures highlight how germline-encoded features drive bnAb-like recognition at early stages. This work provides molecular evidence supporting germline targeting in humans and provides guidance for designing booster immunogens to shepherd affinity maturation toward broad neutralization.
|
| 925. | Ma, Krystal M; Sutton, Henry J; Pratap, Payal P; Steichen, Jon M; Carnathan, Diane; Quinn, James; Kalyuzhniy, Oleksandr; Liguori, Alessia; Agrawal, Sashank; Baboo, Sabyasachi; Madden, Patrick; Cottrell, Christopher A; Willis, Jordan R; Lee, Jeong-Hyun; Landais, Elise; Hu, Xiaozhen; Ramezani-Rad, Parham; Ozorowski, Gabriel; Lewis, Vanessa R; Diedrich, Jolene K; Zhou, Xiaoya; Altheide, Tasha K; Phelps, Nicole; Georgeson, Erik; Alavi, Nushin B; Lu, Danny; Eskandarzadeh, Saman; Kubitz, Michael; Adachi, Yumiko; Mullen, Tina-Marie; Silva, Murillo; Melo, Mariane B; Himansu, Sunny; Irvine, Darrell J; Burton, Dennis R; Yates, John R; Paulson, James C; Sok, Devin; Wilson, Ian A; Silvestri, Guido; Ward, Andrew B; Crotty, Shane; Schief, William R: HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. In: Sci Immunol, vol. 10, no. 110, pp. eadt6660, 2025, ISSN: 2470-9468. (Type: Journal Article | Abstract | Links)
@article{pmid40845127,
An effective prophylactic HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). bnAbs to the Apex region of the HIV envelope glycoprotein (Env) are promising targets for vaccination because of their relatively low somatic hypermutation compared with other bnAbs. Most Apex bnAbs engage Env using an exceptionally long heavy-chain complementarity-determining region 3 (HCDR3) containing specific binding motifs, which reduces bnAb precursor frequency and makes priming of rare bnAb precursors a likely limiting step in the path to Apex bnAb induction. We found that adjuvanted protein or mRNA lipid nanoparticle (LNP) immunization of rhesus macaques with ApexGT6, an Env trimer engineered to bind Apex bnAb precursors, consistently induced Apex bnAb-related precursors with long HCDR3s bearing bnAb-like sequence motifs. Cryo-electron microscopy revealed that elicited Apex bnAb-related HCDR3s had structures combining elements of several prototype Apex bnAbs. These results achieve a critical HIV vaccine development milestone in outbred primates.
|
| 924. | Yuan, Meng; West, Brandyn R; Foreman, William B; Powers, Colin; Feng, Ziqi; Taylor, Ashley L; Yu, Xinye; Wang, Grace; Walker, Laura; Starr, Tyler N; Allen, Robert; Wilson, Ian A: Structural and functional analysis of VYD222: a broadly neutralizing antibody against SARS-CoV-2 variants. In: bioRxiv, 2025, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid40909471,
Extensive mutations in SARS-CoV-2 spike protein have rendered most therapeutic monoclonal antibodies (mAbs) ineffective. However, here we describe VYD222 (pemivibart), a human mAb re-engineered from ADG20 (adintrevimab), which maintains potency despite substantial virus evolution. VYD222 received FDA Emergency Use Authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. Here we show potent neutralization of this antibody against a broad range of emerging variants, including Omicron KP.3 and KP.3.1.1. X-ray crystal structures of VYD222 complexed with the receptor-binding domains of prototype SARS-CoV-2 and Omicron BA.5 demonstrate the binding epitope spans from the receptor binding site to the conserved CR3022 site. Notably, many of the matured residues between ADG20 and VYD222 occur outside the paratopic region. Deep mutational scanning indicates that SARS-CoV-2's ability to escape VYD222 is constrained by structural compatibility and the need to maintain receptor binding. These findings provide crucial insights into the escape-resistant neutralization of VYD222 against a broad panel of clinically relevant SARS-CoV-2 variants and offer valuable guidance for risk assessment of emergent variants.
|
| 923. | Caniels, Tom G; Prabhakaran, Madhu; Ozorowski, Gabriel; MacPhee, Kellie J; Wu, Weiwei; van der Straten, Karlijn; Agrawal, Sashank; Derking, Ronald; Reiss, Emma I M M; Millard, Katrina; Turroja, Martina; Desrosiers, Aimee; Bethony, Jeffrey; Malkin, Elissa; Liesdek, Marinus H; van der Veen, Annelou; Klouwens, Michelle; Snitselaar, Jonne L; Bouhuijs, Joey H; Bronson, Rhianna; Jean-Baptiste, Jalen; Gajjala, Suprabhath; Tehrani, Zahra Rikhtegaran; Benner, Alison; Ramaswami, Mukundhan; Duff, Michael O; Liu, Yung-Wen; Sato, Alicia H; Kim, Ju Yeong; Baken, Isabel J L; Silva, Catarina Mendes; Bijl, Tom P L; van Rijswijk, Jacqueline; Burger, Judith A; Cupo, Albert; Yasmeen, Anila; Phulera, Swastik; Lee, Wen-Hsin; Randall, Kipchoge N; Zhang, Shiyu; Corcoran, Martin M; Regadas, Isabel; Sullivan, Alex C; Brown, David M; Bohl, Jennifer A; Greene, Kelli M; Gao, Hongmei; Yates, Nicole L; Sawant, Sheetal; Prins, Jan M; Kootstra, Neeltje A; Kaminsky, Stephen M; Barin, Burc; Rahaman, Farhad; Meller, Margaret; Philiponis, Vince; Laufer, Dagna S; Lombardo, Angela; Mwoga, Lindsey; Shotorbani, Solmaz; Holman, Drienna; Koup, Richard A; Klasse, Per Johan; Hedestam, Gunilla B Karlsson; Tomaras, Georgia D; van Gils, Marit J; Montefiori, David C; McDermott, Adrian B; Hyrien, Ollivier; Moore, John P; Wilson, Ian A; Ward, Andrew B; Diemert, David J; de Bree, Godelieve J; Andrews, Sarah F; Caskey, Marina; Sanders, Rogier W: Precise targeting of HIV broadly neutralizing antibody precursors in humans. In: Science, vol. 389, no. 6759, pp. eadv5572, 2025, ISSN: 1095-9203. (Type: Journal Article | Abstract | Links)
@article{pmid40373114,
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.
|
| 922. | Juraszek, Jarek; Kadam, Rameshwar U; Branduardi, Davide; van Ameijde, Jeroen; Garg, Divita; Dailly, Nicolas; Jongeneelen, Mandy; Vermond, Jan; Brakenhoff, Just P J; Brandenburg, Boerries; van Dongen, Maria J P; Vogels, Ronald; Friesen, Robert H E; Wilson, Ian A: De novo design of D-peptide ligands: Application to influenza virus hemagglutinin. In: Proc Natl Acad Sci U S A, vol. 122, no. 26, pp. e2426554122, 2025, ISSN: 1091-6490. (Type: Journal Article | Abstract | Links)
@article{pmid40577121,
D-peptides hold great promise as therapeutics by alleviating the challenges of metabolic stability and immunogenicity in L-peptides. However, current D-peptide discovery methods are severely limited by specific size, structure, and the chemical synthesizability of their protein targets. Here, we describe a computational method for de novo design of D-peptides that bind to an epitope of interest on the target protein using Rosetta's hotspot-centric approach. The approach comprises identifying hotspot sidechains in a functional protein-protein interaction and grafting these side chains onto much smaller structured peptide scaffolds of opposite chirality. The approach enables more facile design of D-peptides and its applicability is demonstrated by design of D-peptidic binders of influenza A virus hemagglutinin, resulting in identification of multiple D-peptide lead series. The X-ray structure of one of the leads at 2.38 Å resolution verifies the validity of the approach. This method should be generally applicable to targets with detailed structural information, independent of molecular size, and accelerate development of stable, peptide-based therapeutics.
|
| 921. | Flajnik, Martin F; Stanfield, Robyn L; Verissimo, Ana; Neely, Harold R; Muñoz-Mérida, Antonio; Criscitiello, Michael F; Wilson, Ian A; Ohta, Yuko: Origin of immunoglobulins and T cell receptors: A candidate gene for invasion by the RAG transposon. In: Sci Adv, vol. 11, no. 27, pp. eadw1273, 2025, ISSN: 2375-2548. (Type: Journal Article | Abstract | Links)
@article{pmid40614193,
Rearranging antigen receptors (AgRs) arose when a variable (V) domain exon was invaded by the recombination-activating gene (RAG) transposon ~500 million years ago. We show here that the elasmobranch immunoglobulin heavy (IgH) isotypes-IgM, IgW, and IgNAR-are linked near the αδ T cell receptor (TCRαδ) locus. This linkage presages the emergence of the osteichthyan IgH translocon arrangement and clarifies the relationship between IgH and TCRδs. Recently, we reported , a nonrearranging, elasmobranch major histocompatibility complex (MHC)-linked AgR gene. Here, we describe a nonrearranging paralogue, , linked to this IgM/IgNAR/IgW/TCRαδ gene cluster in an AgR complex (AgRC). UrIg2 amino-terminal domains make homodimers where the C2-C3 structure resembles IgGFc. A relative of the UrIg2 V domain exon was invaded by the RAG transposon, revealing the genesis of the adaptive immune system. Our data indicate that an ancestral chromosome encoded an AgR precursor, undergoing RAG-mediated rearrangement after genome-wide duplication on one chromosome and retaining nonrearranging relics in the MHC and AgRC.
|
| 920. | Feng, Ziqi; Huang, Jiachen; Baboo, Sabyasachi; Diedrich, Jolene K; Bangaru, Sandhya; Paulson, James C; Yates, John R; Yuan, Meng; Wilson, Ian A; Ward, Andrew B: Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein. In: Cell Rep, vol. 44, no. 7, pp. 115941, 2025, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid40618371,
The JN.1-sublineage KP.3.1.1 recently emerged as the globally prevalent SARS-CoV-2 variant, demonstrating increased infectivity and antibody escape. We investigate how mutations and a deletion in the KP.3.1.1 spike protein (S) affect hACE2 binding and antibody escape. Mass spectrometry confirms a new glycan site at residue N30 that alters the glycoforms at neighboring N61. Cryoelectron microscopy (cryo-EM) structures show that the N30 glycan and rearrangement of adjacent residues do not significantly change the overall spike structure, up-down ratio of receptor-binding domains (RBDs), or hACE2 binding. Furthermore, a KP.3.1.1 S with hACE2 structure further confirms an epistatic effect between F456L and Q493E on hACE2 binding. Our analysis shows that SARS-CoV-2 variants that emerged after late 2023 are now incorporating reversions to residues found in other sarbecoviruses, including the N30 glycan, Q493E, and others. Overall, these results inform on the structural and functional consequences of the KP.3.1.1 mutations, the current SARS-CoV-2 evolutionary trajectory, and immune evasion.
|
| 919. | Song, Ge; Yuan, Meng; Liu, Hejun; Capozzola, Tazio; Lin, Ryan N; Torres, Jonathan L; He, Wan-Ting; Musharrafieh, Rami; Dueker, Katharina; Zhou, Panpan; Callaghan, Sean; Mishra, Nitesh; Yong, Peter; Anzanello, Fabio; Avillion, Gabriel; Vo, Anh Lina; Li, Xuduo; Zhang, Yuexiu; Makhdoomi, Muzamil; Feng, Ziqi; Zhu, Xueyong; Peng, Linghang; Nemazee, David; Safonova, Yana; Briney, Bryan; Ward, Andrew B; Burton, Dennis R; Wilson, Ian A; Andrabi, Raiees: Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift. In: Cell Rep, vol. 44, no. 7, pp. 115948, 2025, ISSN: 2211-1247. (Type: Journal Article | Abstract | Links)
@article{pmid40627497,
Developing broad coronavirus vaccines hinges on identifying and understanding the molecular basis of conserved spike epitopes targeted by broadly neutralizing antibodies (bnAbs). Building on our earlier work identifying sarbecovirus receptor-binding domain (RBD) group 1 and 2 bnAbs, we now show that several of these antibodies retain neutralizing activity against highly mutated SARS-CoV-2 variants, including BA.2.86 and JN.1. Structural studies reveal that group 1 bnAbs use recurrent germline-encoded heavy-chain complementarity-determining region 3 (CDRH3) features to interact with a conserved RBD region that overlaps with class 4 bnAb site. Group 2 bnAbs recognize a less well-defined "site V" on the RBD and destabilize spike trimer. Notably, site V remains largely unchanged across SARS-CoV-2 variants and is conserved among diverse sarbecoviruses, highlighting its potential as a broad vaccine target. Our findings underscore the need for targeted vaccine strategies to induce immunofocused B cell responses to escape resistant subdominant spike RBD bnAb epitopes.
|
| 918. | Zhu, Xueyong; Khalil, Ahmed M; Piepenbrink, Michael S; Yu, Wenli; Ma, Yao; Martinez-Sobrido, Luis; Wilson, Ian A; Kobie, James J: Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation. In: bioRxiv, 2025, ISSN: 2692-8205. (Type: Journal Article | Abstract | Links)
@article{pmid40631320,
Monoclonal antibodies (mAbs) that recognize and inhibit a diverse range of influenza viruses, although relatively rare, have been isolated following infection or vaccination. Study of their ontology and mechanisms of action informs universal vaccine and therapeutic development. We have previously described a potent and broad neuraminidase (NA)-neutralizing human mAb, 1122A11, that neutralizes a wide range of H3N2 viruses. Here, further characterization of 1122A11 reveals reactivity to cross-group influenza A virus NAs, including group-1 N1 and N8, and group-2 N2 and N3 NAs. Recent H3N2 viruses have acquired Asn245 glycosylation on the active site rim. Crystal structures of an N2 NA from A/Singapore/INFIMH-16-0019/2016 (H3N2) at 2.3 Å (apo) and 2.2 Å (Fab bound) resolution showed that 1122A11 binding causes local changes to the periphery of NA active site to accommodate the glycan. The CDRH3 of 1122A11 inserts into the active site and mimics the substrate sialic acid. We then determined that the ability of 1122A11 to protect from lethal challenge in mice is not dependent on Fc-effector function. These results highlight the therapeutic potential of 1122A11 as a broad protective anti-viral and reinforce pursuit of immunogen development of NA antibodies toward achieving more universal influenza protection.
|
| 917. | Schleich, Fabian-Alexander; Bale, Shridhar; Guenaga, Javier; Ozorowski, Gabriel; Àdori, Monika; Lin, Xiaohe; Dopico, Xaquin Castro; Wilson, Richard; Chernyshev, Mark; Cotgreave, Alma Teresia; Mandolesi, Marco; Cluff, Jocelyn; Doyle, Esmeralda D; Sewall, Leigh M; Lee, Wen-Hsin; Zhang, Shiyu; O'Dell, Sijy; Healy, Brandon S; Lim, Deuk; Lewis, Vanessa R; Ben-Akiva, Elana; Irvine, Darrell J; Doria-Rose, Nicole A; Corcoran, Martin; Carnathan, Diane; Silvestri, Guido; Wilson, Ian A; Ward, Andrew B; Hedestam, Gunilla B Karlsson; Wyatt, Richard T: Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer. In: Immunity, vol. 58, no. 6, pp. 1598–1613.e8, 2025, ISSN: 1097-4180. (Type: Journal Article | Abstract | Links)
@article{pmid40339576,
The elicitation of cross-neutralizing antibodies to the HIV-1 envelope glycoprotein (Env) by vaccination remains a major challenge. Here, we immunized previously Env-immunized nonhuman primates with a series of near-native trimers that possessed N-glycan deletions proximal to the conserved CD4 binding site (CD4bs) to focus B cells to this region. Following heterologous boosting with fully glycosylated trimers, we detected tier 2 cross-neutralizing activity in the serum of several animals. Isolation of 185 matched heavy- and light-chain sequences from Env-binding memory B cells from an early responder identified a broadly neutralizing antibody lineage, LJF-0034, which neutralized nearly 70% of an 84-member HIV-1 global panel. High-resolution cryoelectron microscopy (cryo-EM) structures revealed a bifurcated binding mode that bridged the CD4bs to V3 across the gp120:120 interface on two adjacent protomers, evading the proximal N276 glycan impediment to the CD4bs, allowing neutralization breadth. This quaternary epitope defines a potential target for future HIV-1 vaccine development.
|
| 916. | Zhou, Han; Zhou, Tonglian; Yu, Wenli; Liu, Liping; Ko, Yeonjin; Johnson, Kristen A; Wilson, Ian A; Schultz, Peter G; Bollong, Michael J: Targeted protein degradation by KLHDC2 ligands identified by high-throughput screening. In: Elife, vol. 14, 2025, ISSN: 2050-084X. (Type: Journal Article | Abstract | Links)
@article{pmid40522120,
Proteolysis-targeting chimeras (PROTACs) enable the selective and sub-stoichiometric elimination of pathological proteins, yet only two E3 ligases are routinely used for this purpose. Here, we expand the repertoire of PROTAC-compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high-throughput screen. We highlight the utility of this ligand with the synthesis of PROTACs capable of potently degrading BRD4 in cells. This work affords additional chemical matter for targeting KLHDC2 and suggests a practical approach for identifying novel E3 binders by high-throughput screening.
|
| 915. | Flores-Garcia, Yevel; Salgado-Jimenez, Berenice; Park, Minah; Mathis-Torres, Shamika; Locke, Emily; MacGill, Randall S; Moskovitz, Re'em; Wilson, Ian A; Zavala, Fidel: Epitope specificity of antibody-mediated protection induced in mice by the malaria vaccine RTS,S/AS01. In: NPJ Vaccines, vol. 10, no. 1, pp. 101, 2025, ISSN: 2059-0105. (Type: Journal Article | Abstract | Links)
@article{pmid40394009,
Antibodies induced by the malaria vaccine RTS,S/AS01 neutralize infectivity of transgenic sporozoites expressing Plasmodium falciparum CSP (PfCSP). These antibodies recognize the junctional, minor repeats, central repeats, and C-term regions of this antigen. The epitope specificity of antibodies mediating protection in mice was characterized in vivo using transgenic sporozoites expressing restricted antigenic portions of PfCSP. In this model, we found protection is mediated mostly by antibodies specific for the central repeats.
|
